Page last updated: 2024-08-16

pipobroman and incb-018424

pipobroman has been researched along with incb-018424 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Moliterno, AR; Stein, BL; Tiu, RV1
Alvarez-Larran, A; Angona, A; Barbui, T; Beggiato, E; Benevolo, G; Bertolotti, L; Betti, S; Bonifacio, M; Cacciola, R; Carli, G; Carobbio, A; Casetti, IC; Cattaneo, D; De Stefano, V; Delaini, F; Di Veroli, A; Elli, EM; Erez, D; Finazzi, G; Fox, ML; Ghirardi, A; Gomez, M; Griesshammer, M; Guglielmelli, P; Iurlo, A; Lunghi, F; Marchetti, M; Masciulli, A; McMullin, MF; Palandri, F; Palova, M; Patriarca, A; Perez-Encinas, M; Recasens, V; Rumi, E; Scaffidi, L; Stephenson, C; Tieghi, A; Vannucchi, AM; Vianelli, N; Wille, K1
Besses, C; Blau, IW; Dong, T; Durrant, S; Francillard, N; Griesshammer, M; Harrison, CN; Hino, M; Kiladjian, JJ; Kirito, K; Masszi, T; Mesa, R; Miller, CB; Moiraghi, B; Pane, F; Passamonti, F; Rosti, V; Rumi, E; Vannucchi, AM; Verstovsek, S; Wroclawska, M; Zachee, P1

Reviews

1 review(s) available for pipobroman and incb-018424

ArticleYear
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
    Annals of hematology, 2014, Volume: 93, Issue:12

    Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression; Fatigue; Health Care Costs; Hemorrhagic Disorders; Humans; Hydroxyurea; Interferons; Janus Kinase 2; Leukemia, Myeloid, Acute; Mutation, Missense; Neoplasms, Second Primary; Nitriles; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quality of Life; Therapies, Investigational; Thrombophilia

2014

Trials

1 trial(s) available for pipobroman and incb-018424

ArticleYear
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
    The Lancet. Haematology, 2020, Volume: 7, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Nitriles; Pipobroman; Polycythemia Vera; Polyethylene Glycols; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Recombinant Proteins; Survival Rate; Time Factors

2020

Other Studies

1 other study(ies) available for pipobroman and incb-018424

ArticleYear
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
    Leukemia, 2019, Volume: 33, Issue:8

    Topics: Antineoplastic Agents; Case-Control Studies; Humans; Hydroxyurea; Neoplasms, Second Primary; Nitriles; Philadelphia Chromosome; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Thrombocythemia, Essential

2019